TC-210の新興薬剤に関する洞察と市場予測：2032年

TCR2 Therapeuticsは、メソセリン陽性の固形がんを標的とするT細胞受容体（TCR）融合コンストラクトT細胞（TRuC-T細胞）の製品候補であるTC-210を開発しています。TC-210 T細胞は、ヒトメソセリンを認識するシングルドメイン抗体を発現し、CD3-epsilonサブユニットに融合した自己遺伝子操作T細胞からなる新規細胞療法であり、発現により内因性T細胞受容体（TCR）複合体に組み込まれます。前臨床試験において、TRuC-T細胞はCAR-T細胞と比較して抗腫瘍活性と持続性に優れ、サイトカイン放出レベルも低いことが示されました。

当レポートでは、主要7ヶ国におけるTC-210市場について調査し、市場の概要とともに、2027年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 悪性胸膜中皮腫（MPM）に対するTC-210の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 TC-210市場評価

• 悪性胸膜中皮腫（MPM）に対するTC-210の市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における悪性胸膜中皮腫（MPM）に対するTC-210の市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: TC-210, Clinical Trial Description, 2023
• Table 2: TC-210, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: TC-210 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: TC-210 Market Size in the US, in USD million (2019-2032)
• Table 7: TC-210 Market Size in Germany, in USD million (2019-2032)
• Table 8: TC-210 Market Size in France, in USD million (2019-2032)
• Table 9: TC-210 Market Size in Italy, in USD million (2019-2032)
• Table 10: TC-210 Market Size in Spain, in USD million (2019-2032)
• Table 11: TC-210 Market Size in the UK, in USD million (2019-2032)
• Table 12: TC-210 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: TC-210 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: TC-210 Market Size in the United States, USD million (2019-2032)
• Figure 3: TC-210 Market Size in Germany, USD million (2019-2032)
• Figure 4: TC-210 Market Size in France, USD million (2019-2032)
• Figure 5: TC-210 Market Size in Italy, USD million (2019-2032)
• Figure 6: TC-210 Market Size in Spain, USD million (2019-2032)
• Figure 7: TC-210 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: TC-210 Market Size in Japan, USD million (2019-2032)

“"TC-210 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about TC-210 for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the TC-210 for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TC-210 for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TC-210 market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM.

Drug Summary:

TCR2 Therapeutics is developing its T-cell receptor (TCR) fusion construct T cells (TRuC-T cells) product candidate, TC-210, which targets mesothelin-positive solid tumors. TC-210 T cells are a novel cell therapy consisting of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human mesothelin, fused to the CD3-epsilon subunit, which, upon expression, is incorporated into the endogenous T-cell receptor (TCR) complex. The company's preclinical studies demonstrated better anti-tumor activity and persistence of TRuC-T cells compared to CAR-T cells while also exhibiting lower levels of cytokine release.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the TC-210 description, mechanism of action, dosage and administration, research and development activities in malignant pleural mesothelioma (MPM).
• Elaborated details on TC-210 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TC-210 research and development activities in MPM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TC-210.
• The report contains forecasted sales of TC-210 for MPM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MPM.
• The report also features the SWOT analysis with analyst views for TC-210 in MPM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TC-210 Analytical Perspective by DelveInsight

• In-depth TC-210 Market Assessment

This report provides a detailed market assessment of TC-210 for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• TC-210 Clinical Assessment

The report provides the clinical trials information of TC-210 for MPM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TC-210 dominance.
• Other emerging products for MPM are expected to give tough market competition to TC-210 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TC-210 in MPM.
• Our in-depth analysis of the forecasted sales data of TC-210 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TC-210 in MPM.

Key Questions

• What is the product type, route of administration and mechanism of action of TC-210?
• What is the clinical trial status of the study related to TC-210 in malignant pleural mesothelioma (MPM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TC-210 development?
• What are the key designations that have been granted to TC-210 for MPM?
• What is the forecasted market scenario of TC-210 for MPM?
• What are the forecasted sales of TC-210 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to TC-210 for MPM?
• Which are the late-stage emerging therapies under development for the treatment of MPM?

Table of Contents

1. Report Introduction

2. TC-210 Overview in MPM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. TC-210 Market Assessment

• 5.1. Market Outlook of TC-210 in MPM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of TC-210 in the 7MM for MPM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of TC-210 in the United States for MPM
  • 5.3.2. Market Size of TC-210 in Germany for MPM
  • 5.3.3. Market Size of TC-210 in France for MPM
  • 5.3.4. Market Size of TC-210 in Italy for MPM
  • 5.3.5. Market Size of TC-210 in Spain for MPM
  • 5.3.6. Market Size of TC-210 in the United Kingdom for MPM
  • 5.3.7. Market Size of TC-210 in Japan for MPM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options